Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRRO NASDAQ:KYTX NASDAQ:STRO NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRROKorro Bio$11.61+3.7%$12.26$5.20▼$55.89$161.53M3.07112,808 shs231,201 shsKYTXKyverna Therapeutics$8.67-2.6%$9.05$2.24▼$13.67$541.08M2.05940,529 shs498,577 shsSTROSutro Biopharma$25.57-16.5%$29.81$6.74▼$43.85$507.39M1.63284,058 shs708,136 shsTECXTectonic Therapeutic$29.12+2.1%$29.65$14.39▼$36.03$538.15M3.27233,828 shs109,613 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRROKorro Bio+11.89%+1.08%-16.98%+0.81%-24.32%KYTXKyverna Therapeutics+3.85%-17.13%-8.34%+15.89%+302.71%STROSutro Biopharma-1.64%-20.30%-10.86%+66.23%+265.26%TECXTectonic Therapeutic-1.11%-4.30%+3.18%+33.46%+26.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRROKorro Bio$11.61+3.7%$12.26$5.20▼$55.89$161.53M3.07112,808 shs231,201 shsKYTXKyverna Therapeutics$8.67-2.6%$9.05$2.24▼$13.67$541.08M2.05940,529 shs498,577 shsSTROSutro Biopharma$25.57-16.5%$29.81$6.74▼$43.85$507.39M1.63284,058 shs708,136 shsTECXTectonic Therapeutic$29.12+2.1%$29.65$14.39▼$36.03$538.15M3.27233,828 shs109,613 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRROKorro Bio+11.89%+1.08%-16.98%+0.81%-24.32%KYTXKyverna Therapeutics+3.85%-17.13%-8.34%+15.89%+302.71%STROSutro Biopharma-1.64%-20.30%-10.86%+66.23%+265.26%TECXTectonic Therapeutic-1.11%-4.30%+3.18%+33.46%+26.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRROKorro Bio 2.82Moderate Buy$16.7145.03% UpsideKYTXKyverna Therapeutics 2.67Moderate Buy$30.00246.38% UpsideSTROSutro Biopharma 3.00Buy$48.2589.37% UpsideTECXTectonic Therapeutic 2.86Moderate Buy$79.83173.97% UpsideCurrent Analyst Ratings BreakdownLatest KRRO, STRO, KYTX, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026KRROKorro Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.005/18/2026KRROKorro Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.005/18/2026KRROKorro Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.005/15/2026STROSutro Biopharma Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$38.00 ➝ $43.005/15/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.005/15/2026STROSutro Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $50.005/13/2026KYTXKyverna Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $29.005/8/2026STROSutro Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026KRROKorro Bio JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/4/2026STROSutro Biopharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/1/2026STROSutro Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRROKorro Bio$6.39M26.01N/AN/A$8.29 per share1.39KYTXKyverna TherapeuticsN/AN/AN/AN/A$3.22 per shareN/ASTROSutro Biopharma$102.48M4.12N/AN/A($4.04) per share-6.31TECXTectonic TherapeuticN/AN/AN/AN/A$12.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRROKorro Bio-$117.26M-$11.67N/AN/AN/A-1,834.48%-117.86%-71.04%N/AKYTXKyverna Therapeutics-$161.31M-$3.28N/AN/AN/AN/A-81.88%-64.87%N/ASTROSutro Biopharma-$191.09M-$11.04N/AN/AN/A-154.21%N/A-69.20%8/6/2026 (Estimated)TECXTectonic Therapeutic-$74.15M-$4.46N/AN/AN/AN/A-32.33%-30.92%8/6/2026 (Estimated)Latest KRRO, STRO, KYTX, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026STROSutro Biopharma-$2.7363-$2.94-$0.2037-$2.94$8.89 million$14.52 million5/12/2026Q1 2026KYTXKyverna Therapeutics-$0.75-$0.66+$0.09-$0.66N/AN/A5/7/2026Q1 2026KRROKorro Bio-$1.60-$1.69-$0.09-$1.69$0.76 millionN/A5/7/2026Q1 2026TECXTectonic Therapeutic-$1.16-$1.34-$0.18-$1.34N/AN/A3/26/2026Q4 2025KYTXKyverna Therapeutics-$0.80-$0.80N/A-$0.80N/AN/A3/12/2026Q4 2025KRROKorro Bio-$1.93-$5.32-$3.39-$5.32$0.43 million$1.29 million2/26/2026Q4 2025TECXTectonic Therapeutic-$1.11-$1.03+$0.08-$1.03N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKRROKorro BioN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRROKorro BioN/A8.138.13KYTXKyverna Therapeutics0.138.158.15STROSutro BiopharmaN/A3.123.12TECXTectonic TherapeuticN/A18.5118.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRROKorro Bio13.18%KYTXKyverna Therapeutics18.08%STROSutro Biopharma96.99%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipKRROKorro Bio4.80%KYTXKyverna Therapeutics17.60%STROSutro Biopharma3.60%TECXTectonic Therapeutic39.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRROKorro Bio7014.42 million13.73 millionNo DataKYTXKyverna Therapeutics9660.79 million50.10 millionOptionableSTROSutro Biopharma24016.57 million15.97 millionOptionableTECXTectonic Therapeutic12018.87 million11.36 millionN/AKRRO, STRO, KYTX, and TECX HeadlinesRecent News About These CompaniesTectonic Therapeutics: Currently In A Catalyst VacuumMay 19 at 1:42 PM | seekingalpha.comLifeSci Capital Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)May 17, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)May 11, 2026 | theglobeandmail.comTectonic Therapeutic (NASDAQ:TECX) Issues Quarterly Earnings Results, Misses Expectations By $0.18 EPSMay 8, 2026 | marketbeat.comTectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comTectonic Therapeutic (NASDAQ:TECX) Insider Marcella Ruddy Sells 1,065 SharesMay 7, 2026 | insidertrades.comInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,065 Shares of StockMay 6, 2026 | marketbeat.comTectonic Therapeutic (TECX) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Consensus Rating of "Moderate Buy" from BrokeragesApril 29, 2026 | marketbeat.comTectonic Therapeutic Appoints Jessica Chutter to Board of DirectorsApril 23, 2026 | globenewswire.comStifel initiates coverage of Tectonic Therapeutic (TECX) with buy recommendationApril 16, 2026 | msn.comTectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2April 16, 2026 | seekingalpha.comInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,000 Shares of StockApril 4, 2026 | insidertrades.comTectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLCMarch 15, 2026 | defenseworld.netDInsider Selling: Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 6,262 Shares of StockMarch 10, 2026 | insidertrades.comTectonic Therapeutic Announces Leadership Transition and New ChairMarch 9, 2026 | theglobeandmail.comStocks showing market leadership: Tectonic Therapeutic earns 96 RS ratingMarch 9, 2026 | msn.comTectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference TranscriptMarch 6, 2026 | seekingalpha.comTectonic Therapeutic (NASDAQ:TECX) Insider Sells 1,649 SharesMarch 6, 2026 | insidertrades.comTectonic Therapeutic, Inc. Reports Positive Phase 1b Results for TX45 in Pulmonary Hypertension and Advances TX2100 into Phase 1a Trial for Hereditary Hemorrhagic TelangiectasiaFebruary 26, 2026 | quiverquant.comQTectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsFebruary 26, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBeyond NVIDIA: Picks-and-Shovels AI Plays with Strong MomentumBy Chris Markoch | May 10, 2026Microsoft Earnings Look Strong, But Investors Focus on RisksBy Chris Markoch | April 30, 2026Palantir Is Down 30%: Noise? Or a Signal to Accumulate?By Chris Markoch | April 28, 2026Is Oracle Undervalued as Cloud Growth Accelerates?By Thomas Hughes | April 29, 20263 AI Small-Cap Stocks With Strong Insider and Institutional Buy-InBy Thomas Hughes | April 23, 2026KRRO, STRO, KYTX, and TECX Company DescriptionsKorro Bio NASDAQ:KRRO$11.61 +0.41 (+3.66%) Closing price 04:00 PM EasternExtended Trading$12.39 +0.78 (+6.72%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Kyverna Therapeutics NASDAQ:KYTX$8.67 -0.23 (-2.58%) Closing price 04:00 PM EasternExtended Trading$8.82 +0.15 (+1.78%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Sutro Biopharma NASDAQ:STRO$25.57 -5.05 (-16.49%) Closing price 04:00 PM EasternExtended Trading$25.82 +0.25 (+0.97%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Tectonic Therapeutic NASDAQ:TECX$29.12 +0.60 (+2.10%) Closing price 04:00 PM EasternExtended Trading$29.16 +0.04 (+0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
